title: Practice pattern of gastroenterologists for the management of GERD under the minimal influence of the insurance reimbursement guideline: a multicenter prospective observational study.
abstract: The objective of the study was to document practice pattern of gastroenterologists for the management of gastroesophageal reflux disease (GERD) under the minimal influence of the insurance reimbursement guideline. Data on management for 1,197 consecutive patients with typical GERD symptoms were prospectively collected during 16 weeks. In order to minimize the influence of reimbursement guideline on the use of proton pump inhibitors (PPIs), rabeprazole was used for the PPI treatment. A total of 861 patients (72%) underwent endoscopy before the start of treatment. PPIs were most commonly prescribed (87%). At the start of treatment, rabeprazole 20 mg daily was prescribed to 94% of the patients who received PPI treatment and 10 mg daily to the remaining 6%. At the third visits, rabeprazole 20 mg daily was prescribed to 70% of those who were followed and 10 mg daily for the remaining 30%. Continuous PPI treatment during the 16-week period was performed in 63% of the study patients. In conclusion, a full-dose PPI is preferred for the initial and maintenance treatment of GERD under the minimal influence of the insurance reimbursement guideline, which may reflect a high proportion of GERD patients requiring a long-term treatment of a full-dose PPI.
authors.affiliation: Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
authors.forename: Kwang Jae
authors.initials: KJ
authors.lastname: Lee
authors.forename: Jin Il
authors.initials: JI
authors.lastname: Kim
authors.forename: Ju Sang
authors.initials: JS
authors.lastname: Park
authors.forename: Byung Sik
authors.initials: BS
authors.lastname: Moon
authors.forename: Sang-Gyun
authors.initials: SG
authors.lastname: Kim
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Chun
authors.forename: Hoon-Yong
authors.initials: HY
authors.lastname: Jung
authors.forename: Chang Hwan
authors.initials: CH
authors.lastname: Choi
authors.forename: Seong Woo
authors.initials: SW
authors.lastname: Chun
authors.forename: Geun Am
authors.initials: GA
authors.lastname: Song
authors.forename: Myung Gyu
authors.initials: MG
authors.lastname: Choi
authors.forename: Hoon Jai
authors.initials: HJ
authors.lastname: Chun
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors; D005260:Female; D005762:Gastroenterology; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000188:drug therapy*; D019983:Guideline Adherence; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D064750:Rabeprazole; D056910:Republic of Korea; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064750:Rabeprazole